MedTrace Logo

Ranibizumab to Treat Type 2 Idiopathic Macular Telangiectasia (RAMA-Trial)

NCT00504400 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2009-09-22

No results posted yet for this study

Summary

The purpose of this study is to investigate if a new drug called ranibizumab is effective to treat a rare bilateral disease of the macula: type 2 idiopathic macular telangiectasia (type 2 IMT). 10 patients will receive monthly injections of the drug into one eye over a period of one year.

Conditions

  • Type 2 Idiopathic Macular Telangiectasia

Interventions

DRUG

Intravitreal injection ranibizumab

Monthly intravitreal injection of of 0.5mg ranibizumab in one eye over one year

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • University Hospital, Bonn

    lead OTHER

Principal Investigators

  • Frank Holz, MD · University of Bonn, Department of Ophthalmology

  • Hendrik PN Scholl, MD, MA · University of Bonn

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31
Primary Completion
2009-06-30
Completion
2009-09-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00504400 on ClinicalTrials.gov